Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  hypoxia-activated prodrug TH-302
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-CR-408, NCI-2012-00508, NCT01522872
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-CR-413, NCI-2014-01834, NCT01864538
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TH-CR-415, NCI-2014-01327, NCT02093962
Hypoxia-Activated Prodrug TH-302 and Bevacizumab in Treating Patients with Glioblastoma Multiforme That Has Progressed after Previous Bevacizumab Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-0105, NCI-2013-00827, CTRC# 12-0105, HSC20130212H, NCT02342379
Hypoxia-Activated Prodrug TH-302 and Pazopanib Hydrochloride in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00031123, NCI-2013-02202, NCT01485042
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: EMR200592-006, NCI-2014-00662, NCT02047500
Start Over